Skip to main content
Premium Trial:

Request an Annual Quote

Ontario Genomics Institute Makes Second Investment in Amorfix to Support Alzheimer's Dx

NEW YORK (GenomeWeb News) - The Ontario Genomics Institute has made a second investment of Can$50,000 (US$44,687) in Amorfix Life Sciences to support development of a blood test for Alzheimer's disease, Amorfix said today.
 
Amofrix issued 47,619 common shares and 23,810 warrants to Genomics Ontario, the investment arm of the institute.
 
Each warrant entitles the holder to purchase one common share of Amorfix at an exercise price of $1.05 for a term of two years. Both the shares and warrants are subject to a four-month hold period.
 
Amorfix is developing a blood test for Alzheimer’s disease, EP-AD, based upon its patent-pending Epitope Protection technology.
 
OGI made its first investment in January.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.